Decoded – Details, episodes & analysis

How do we move from discovery to action in the fight against cancer?

In this inaugural episode of the Decoded podcast, Dr. Jurgi Camblong speaks with Professor Umberto Malapelle, one of the leading voices in molecular diagnostics and liquid biopsy, to explore how precision data is reshaping the fight against cancer.

Together, they decode the evolving role of pathology, tracing the shift from glass slides to genomic signals and the rise of liquid biopsy as a dynamic, non-invasive tool in cancer care.

Professor Malapelle reveals how integrating molecular insights is making diagnostics more precise, accessible, and equitable - while empowering clinicians to personalize treatment at scale.

The conversation unpacks the real-world impact of liquid biopsy, the economics of molecular testing, and why the future of cancer care depends on both collaboration and a new generation of digitally fluent healthcare professionals.

Listen in for:

• Insights on where cancer diagnostics is heading
• The power - and challenge - of integrating complex data in medicine
• Why liquid biopsy is more than a buzzword

This is the future of oncology, decoded.

Explore more: https://www.sophiagenetics.com/podcasts/

Cancer has been described for a long time, yet only now are we beginning to truly decode it.

In this episode of Decoded, Dr. Jurgi Camblong, Founder of SOPHiA GENETICS, speaks with Dr. Pedram Razavi, Director of Liquid Biopsy and Cancer Genomics at Memorial Sloan Kettering Cancer Center. 

From the first historical mentions of tumors to today’s breakthroughs in precision oncology, Dr. Razavi shares how genomics, liquid biopsy, and AI are reshaping the way we detect, treat, and even think about cancer. Along the way, Dr. Razavi shares personal stories - the human moments that drive discovery.

In this exciting episode of Decoded, you'll hear:

• The evolving definition of cancer - what makes cancer “selfish,” and why some tumors adapt
• How breast oncology helped pioneer precision medicine
• Why liquid biopsy may let us anticipate resistance before it appears
• The art of oncology: data, science, and the patient in front of you

This conversation bridges history, science, and the future - for clinicians and researchers, patients and families, and anyone who wants to understand how cancer care is changing.

In this episode of Decoded, Dr. Jurgi Camblong, Founder SOPHiA GENETICS, speaks with Dr. David Rhew, Global Chief Medical Officer at Microsoft and adjunct professor at Stanford University, to explore how responsible AI, multimodal data, and collective intelligence are reshaping global healthcare.

From his early fascination with arcade games to his leadership at Microsoft, Dr. Rhew shares a unique journey that blends computer science, clinical practice, and visionary health technology.

Together, they explore:

• Why building trust in AI is fundamental to healthcare transformation
• What multimodal data means for personalized, predictive medicine
• How technology can drive equity and scale across underserved regions
• The cultural and regulatory barriers that still stand in the way

Dr. Rhew also offers timely insights on what the next decade holds for diagnostics, prescribing, and healthcare collaboration - and his advice for the next generation of innovators in technology and medicine.

This is a candid, visionary conversation about the future of care: data-powered, human-centered, and globally connected.

A Conversation with Parminder Bhatia, Chief AI Officer, GE HealthCare

After three episodes with leaders in oncology and medicine - Prof. Malapelle (International Society of Liquid Biopsy), Dr. David Rhew (Microsoft), and Dr. Pedram Razavi (MSK), Jurgi turns to the question everyone’s asking:

How do we move from impressive demos to real impact at the bedside—at scale?

In this episode, Dr. Jurgi Camblong, Founder SOPHiA GENETICS, speaks with Parminder “Parry” Bhatia, Chief AI Officer at GE HealthCare, to unpack the hard parts of AI in medicine: earning clinical trust, fitting into workflows, proving value, and scaling safely across complex systems.

You’ll hear about:

• Adoption as the KPI
• The validation moat - building clinical-grade trust, calibration, and governance.
• Foundation models in imaging
• Real impact of AI in healthcare
• What’s next - agentic AI for tumor-board style decision support, and training clinicians to treat AI like a co-pilot they can question.

If you’re investing in, building, or deploying clinical AI, this is the playbook teams will be sharing. Listen on Spotify or Apple Podcasts.